SpeeDx Increase Distribution Network
18.3.2021 10:00:00 EET | Business Wire | Press release
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx Resistance Plus® and Plex PCR® tests. Neogen Diagnostik Sağlık Hizmetleri Ltd Şti will distribute all SpeeDx tests throughout Turkey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005254/en/
“Neogen Diagnostik are a great fit for SpeeDx products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners.” - Warwick Need, SpeeDx Director of Sales (Graphic: Business Wire)
“We continue to see demand for our key tests and technology around the world,” says Warwick Need, SpeeDx Director of Sales. “Neogen Diagnostik are a great fit for SpeeDx products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners.”
In addition to Resistance Plus GC* - combining Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility, and Resistance Plus MG* - simultaneously detecting Mycoplasma genitalium and genetic markers for azithromycin resistance, the SpeeDx sexual health portfolio includes Plex PCR VHS* - a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis), and Plex PCR HSV-1&2, VZV.
SpeeDx are also growing their Respiratory portfolio with the recently launched Plex PCR RespiVirus - a comprehensive multiplex panel for respiratory virus testing, and the soon to be launched Plex PCR SARS-CoV-2 test – a dual target COVID-19 assay for confident detection of all currently known circulating variants. A respiratory bacterial infection testing solution will also be launched this year.
“Neogen Diagnostik is pleased to make Resistance Guided Therapy available to all stakeholders in the Turkey healthcare chain from clinicians and lab specialists to patients through this distributorship deal with SpeeDx. This is absolutely of medical value complementing the rational use of antibiotics when treating patients. SpeeDx solutions will be a real diagnostic tool for clinicians when deciding on the best possible treatment options for their patients,” Abdulmecit Arikan, founder of Neogen Diagnostik, said in a statement.
*available where CE-mark is accepted, not available in the U.S.
About SpeeDx Pty Ltd
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx Resistance Plus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
About Neogen Diagnostik Sağlık Hizmetleri Ltd Şti
Neogen Diagnostik is a medical company founded by Abdulmecit Arikan, a Molecular Biologist with 18 years of experience in executive positions at a leading multinational diagnostics company and 20+ years corporate experience. Neogen Diagnostik is committed to providing access to advanced technologies used for diagnostic purposes in healthcare, believing that innovative technologies with value-based solutions can eliminate the existing obstacles in molecular diagnostics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005254/en/
Contact information
Madeline O’Donoghue
Global Marketing Director
madelineo@speedx.com.au
+61 2 9209 4170
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
What Europeans Really Want From Their Next Smartphone13.10.2026 14:01:00 EEST | Press release
If you’ve ever bought running shoes for the runner you hoped to become or luggage for a yet to be planned trip, you’re not alone. New research from Samsung reveals that Europeans1 take a similar aspirational approach when choosing a smartphone. More than two thirds (66%2) of Europeans surveyed1 chose their current smartphone with at least one interest they wanted to pursue in mind, with interests ranging from entertainment and side hustles to gaming, travel and content creation. In fact, almost half (46%3) consider their ambitions when making technology choices, including 24% who say their choices are primarily shaped by the life they aspire to lead. Additionally, almost a third (28%) reported that they chose their current smartphone to better reflect their personal style. Having a variety of options to choose from is important when considering the wide range of aspirations and focuses of European consumers. Big ambitions, everyday needs Europeans1 may be choosing smartphones with futu
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules13.10.2026 14:00:00 EEST | Press release
Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform. Enodia’s proprietary platform enables selective Sec61 Translocon modulation, a novel approach to inhibit disease-driving proteins at the point of synthesis before pathological effects occur, while preserving essential physiological functions. Enodia has built a broad and well-characterized chemical space spanning multiple Sec61 inhibitor families, supported by extensive biological datasets, including proteomics, cryo-EM and tailored cell-line libraries that enable rational small-molecule design powered by machine learning. “Enodia has built a broad platform t
TradingHub Appoints Phil Snow as Chairman13.10.2026 12:00:00 EEST | Press release
TradingHub today announced the appointment of Phil Snow as Chairman, further strengthening the company's leadership as it continues to expand its global presence and invest in innovation across trade surveillance. Phil brings three decades of experience in financial technology, data and analytics, built at FactSet, where he served as Chief Executive Officer from 2015 to 2025. Under his leadership, FactSet more than doubled its revenue, joined the S&P 500 and expanded its products and global presence. The appointment follows TradingHub's recent investment from Nordic Capital and reflects the shared ambition to support the company's next phase of growth while building on the strong foundations established by its leadership team. "Phil is an outstanding appointment for TradingHub, and I am delighted to welcome him as Chairman," said Mike Coats, Chief Executive Officer of TradingHub. "He spent a decade running a global financial data company that serves many of the same institutions we do,
Bregal Milestone Backs Asolvi to Build AI-First Field Service Software for Compliance-Critical Industries13.10.2026 11:00:00 EEST | Press release
Bregal Milestone, a leading European growth private equity firm specialising in software, today announced a majority investment in Asolvi, a provider of field service management (FSM) software for compliance-critical and asset-intensive industries. Bregal Milestone is acquiring its stake from Volpi Capital and Viking Growth. CEO Nick Barnett and the management team are reinvesting alongside Bregal Milestone. Founded in 1991 and headquartered in Trondheim, Norway, Asolvi serves more than 2,000 customers across the UK, DACH, the Nordics, Spain and Latin America. For fire and security installers and utility contractors, Asolvi’s software is the operating system of the business. It schedules engineers, manages maintenance contracts, records inspections, and produces evidence that regulators, insurers and building owners require. Because Asolvi sits at the centre of these workflows, it captures structured data on assets, inspections, parts, and outcomes as jobs are completed. This puts Asol
YouHodler Italy Authorised by CONSOB as a Crypto-Asset Service Provider Under MiCA13.10.2026 10:00:00 EEST | Press release
YouHodler Italy S.r.l., announces that CONSOB, after hearing the Bank of Italy, has authorised it as a crypto-asset service provider (CASP) under Regulation (EU) 2023/1114 (MiCA) and Legislative Decree 129/2024, by resolution no. 24156 of 8 October 2026. The authorisation covers five services: custody and administration of crypto-assets on behalf of clients; exchange of crypto-assets for funds; exchange of crypto-assets for other crypto-assets; execution of orders on behalf of clients; and transfer services for crypto-assets on behalf of clients. With the authorisation, YouHodler Italy serves clients in Italy as a supervised firm under MiCA's client protections: segregation of client crypto-assets, governance and security requirements, pre-contractual information and complaints handling. The company plans to extend its services to all 27 EU Member States through the procedure set out in the Regulation. "The CONSOB authorisation is the result of long and rigorous work with the authoriti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom